Targacept to Discontinue Overactive Bladder Program

Targacept Inc. said it would abandon further development of TC-5214 as a treatment for overactive bladder after seeing disappointing results in a midstage study.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news